Background: Epilepsy is a serious and complex central nervous system disorder associated with recurrent episodes of convulsive seizures due to the imbalance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmitters level in the brain. The available treatments are neither competent to control the seizures nor prevent progress of disease. Since ages, Herbal medicines have remained important sources of medicines in many parts of world which is evidenced through their uses in traditional systems of medicine i.e. Ayurveda, Siddha, Unani, Homeopathy and Chinese etc. Aim: A polyherbal formulation (containing Terminalia chebula Retz., Asparagus racemosus Willd., Embelia ribes Burm. F, Acorus calamus L., Tinospora cordifolia (Willd.) Miers, Convolvulus pluricaulis Choisy, Saussurea lappa C.B.Clarke, Achyranthes aspera L.) is mentioned in Ayurvedic classics Bhaiṣajya Ratnāvali. The aim of the study was to evaluate the anticonvulsant activity of the formulation in Maximum electroshock and Pentylenetetrazole induced convulsions in rats. Materials and Methods: In the present study, a polyherbal formulation was developed as directed by classical text and evaluated for the anticonvulsant activity using Maximal Electroshock Shock (MES) and Pentylenetetrazole (PTZ) induced convulsions in rats. Statistical comparison was done by one way ANOVA followed by the Tukey's multiple comparison test. Results: The obtained results showed that the PHF had a protective role on epilepsy. Treatment with PHF significantly improves antioxidant enzymes activities of superoxide dismutase (SOD) and glutathione (GSH) levels significantly as compared to controls. PHF also significantly decreased malonaldialdehyde (MDA) levels in the brain. Moreover, it also attenuated the PTZ-induced increase in the activity of GABA-T in the rat brain. Conclusion: These findings suggest that PHF might have possible efficacy in the treatment of epilepsy.
change the ESR value of the patients, which is a prognostic marker for inflammation. Treatment with test formulation and combination therapy brought down the inflammation as can be evidently seen from the reduction in mean ESR values of the patients. Most significant effect on ESR value due to treatment was seen in Group III patients. All the 3 treatment groups showed significant improvement in the Hemoglobin levels. Most significant effect on hemoglobin level due to treatment was seen in Group III patients [ Table 16 ].
Cumulative scores for abdominal pain, diarrhea, stool consistency and bowel frequency/day of patients were calculated on different treatments in correlation with their baseline characteristics and quality of life [ Table 17 ].
Decrease in the suffering of patients was noted as evidenced from symptomatic improvement, shown in the 10 ( 
Adverse effects
Patients treated with monoherbal therapy and combination therapy did not report any side effects, relapse or complications while 5 (50%) patients treated with Mesalamine exhibited the relapse of the symptoms such as diarrhea and flatulence after drug withdrawal.
Discussion
A monoherbal formulation containing Holarrhena antidysenterica extract was used to evaluate its efficacy and safety in patients with chronic ulcerative colitis. Herbal formulations with single ingredient can be tested for their efficacy, safety and cost in comparison with modern allopathic drugs and surgical procedures. By reducing dose of Allopathic drugs, side effects can be minimised. The results from this study may offer insights for the development of novel, effective and satisfactory herbal formulations.
In our patient population, more prevalence was observed in 31-40 and 51-60 years of age and 60% patients out of total 30 patients having UC were males. The epidemiological data and theories behind the pathophysiology of IBD reported were found to be correlating with our clinical study. Kelvin Thia in 2008 [11] and Cosnes Jacques in 2011 [12] reported that the peak age for UC is 30-40 years with slight male predominance. 30% of patients enrolled for the study had the habit of smoking. The treatment with test drug reduced the (n=17) 13.8±1.5 7.4±1.1*** 14.9±1.32 6.91±0.21*** 13.5±0.38 6.3±0.51*** Data is represented as mean±SEM. Statistical analysis was carried out using paired t-test and Kruskal-Wallis test followed by the Dunn's post hoc test. ***Significant difference before and after the treatment in same group P<0.0001. SEM: Standard error of mean high scores for signs and symptoms for ulcerative colitis in all smokers as well as nonsmokers. The strongest environmental risk factor for IBD is tobacco smoking but in 1998, Zijistra [13] reported that current smoking is protective against UC.
In our study 80% patients inspite of leading active lifestyle were suffering from UC which probably could be due to their stressful jobs, insecurity, higher workload, financial stress and a lackadaisical attitude towards personal health. People leading active life with outdoor activities have not been found to suffer from UC. [14] In our studies, 70% patients were experiencing stress due to financial problems, overwork and poor health. Higher mortality from IBD has been reported in managerial, clerical, and sales positions, which typically involve sedentary and indoor work. All the treatments in the present study reduced mucus in stools. Stress increases the risk of developing IBD. Stress causes neuroendocrine response which decreases the mucus secretion and thereby weakens the mucosal barrier and increases the permeability. An impaired colonic mucosal barrier leading to increased intestinal permeability has been demonstrated in patients with UC. Local leaks due to apoptosis of colonic epithelium and highly permeable ulcerous lesions comprise the primary lesion in mild UC. [15] All the patients of our study, vegetarian or non-vegetarian, were regular consumers of street food. They had complaints of intermittent diarrhea and constipation along with flatulence. They expelled mucus and blood in their feces and suffered gastrointestinal infections. These symptoms were reduced after the treatment with test drug. The scores were significantly different before and after the treatment. IBD is most prevalent in developed regions. It is postulated that this is the result of "westernization" of lifestyle, such as changes in diet, smoking and variances in exposure to sunlight, pollution, and industrial chemicals. [16] Higher intake of fatty acids, sucrose, and fast food increases the risk of IBD.
Most of the patients had complaints of loose motions or watery diarrhea before treatment. All the patients showed positive result for occult blood test done in stool samples which reversed significantly in all the treatment groups. Rise in hemoglobin levels of the patients after the trial treatments could be due to decreased blood loss through feces. The clinical studies conducted in 30 patients of ulcerative colitis, irrespective of their etiology showed a marked reduction in the frequency and consistency score of the stools after the test drug treatment. Patients suffering from several years with chronic diarrhea responded positively to the trial treatments. Patients treated with monoherbal tablets alone showed maximal reduction in abdominal pain, diarrhea, and bowel frequency per day and had better stool consistency scores and the results were better than Mesalamine treated patients. The treatment reduced the colonic inflammation as evident from ESR value. Patients with UC have also demonstrated decreased colonic mucin. An in-vitro study demonstrated a possible interaction between bacterial peptides and the mucosa in UC, resulting in depletion of mucus secretion by goblet cells [17] and excessive mucus expulsion in stool after colonic damage. Microbes are considered as antigens which lead to activation of intestinal immune system and epithelial cells. Release of various inflammatory mediators cause local mucosal damage. [18] Blood is almost always present in stools of IBD patients. Medical therapy leading to remission improves gut barrier integrity. Thus, the results were similar to our pre-clinical studies in which the methanolic extract of Holarrhena antidysenterica showed beneficial effects and reduced stool consistency scores. [19] In the present study, patients were found to have stool infection on the day of enrollment for study. Treatment with Monoherbal tablet alone and in combination with Mesalazine significantly reduced the stool infection while Mesalamine alone could not resolve the infection. This property of controlling infection in monoherbal treatment will be an additional benefit over Mesalamine alone. Gastrointestinal infections such as amoebic dysentery are the major and most frequent problems found in IBD patients. Traditionally Holarrhena antidysenterica has been useful in amoebic dysentery and diarrhea. Holarrhena antidysenterica showed promising activity against experimental amoebiasis in rats and hamsters, [20] The fruit extract (50% ethanolic) showed antiprotozoal effect against Enta. histolytica strain STA and Trypanosoma evansi. [21] Clinical tests with connessine, which is the important alkaloid of Holarrhena antidysenterica showed anti amoebic activity with intestinal and hepatic amoebiasis patients. All the treatments significantly reduced the cumulative scores for abdominal pain, diarrhea, stool consistency and bowel frequency/day in all the patients irrespective of their smoking habit, type of stress, age, food habits or chronicity of symptoms. In the context of these reports and the observations obtained in our study, we can conclude that the monoherbal test formulation alone and in combination with Mesalamine showed significant improvement in combating the clinical symptomatology of IBD.
Patients treated with monoherbal therapy and combination therapy did not report any side effects, relapse or complications while 50% patients treated with Mesalamine exhibited relapse of the symptoms such as diarrhea and flatulence after drug withdrawal. The most common problem existing with Aminosalicylates class of drugs prescribed quite often for the treatment of IBD is relapse on stoppage of treatment even after the regression of the symptoms. Any therapy which provides relief from symptoms and treats the disease at basic level and improves the quality of life of patients suffering from distressing disease like IBD would be easily acceptable. Thus, the monoherbal preparation had a low overall cost of treatment along with benefits of similar efficacy, safety and less chances of relapse when compared to available conventional treatments like salicylates, steroids, antidiarrheals etc., Thus, the efficacy observed in ulcerative colitis patients treated with monoherbal formulation containing extracts of Holarrhena antidysenterica and the group treated with both herbal and Mesalamine was found to be better than the group treated with Mesalamine alone.
Conclusion
The clinical study supports the efficacy of investigational drug Holarrhena antidysenterica extract in resolving chronic ulcerative colitis with fewer chances of relapse and side effects. "Monoherbal" therapies may be used if found safe and effective as it will be easier to analyze the constituents as well as the mechanism of action. The results obtained in the present study can be used to conduct Phase II and III clinical trials with larger sample size and determine the problems associated with the management of IBD.
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Introduction
Epilepsy is one of the most widespread serious neurological conditions which affects approximately 1-2% of the world population with an annual prevalence of 50-100,000 per year. [1] More than 10 million people suffer from this disease in India. [2] The disease is characterized by brief episodes of seizures and excessive EEG discharge generally associated with the loss of consciousness with body movements (convulsions).
[3] Epileptic seizures often cause temporary mutilation of perception, leaving the person at threat of physical damage. [4, 5] Imbalance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmitters levels in the central nervous system (CNS) is widely accepted as the mechanism for pathogenesis of epilepsy. [6] Reduction in the concentration of GABA may result in many pathological alterations in the CNS and may manifest as convulsions. [7] Approximately 35% of the patients continue to have seizures and do not respond satisfactorily to regular pharmacological remedies using barbiturates, hydantoin and benzodiazapines that constitute the first line of treatment. [8] Typical antiepileptic treatments are unable to control seizures effectively and do not prevent progressive epileptogenic changes which are not well understood. [9] The available drugs are neither completely effective nor constantly safe and are usually associated with unwanted effects, toxicity and teratogenicity. [9] There is also a possibility of drug interaction with other drugs as epilepsy requires long term therapy. Epilepsy still continues as a neurological disorder in anticipation of safer drugs with enhanced therapeutic efficiency. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com predicts that about 80% of world's epileptic patients live in developing countries and most of them do not get proper medical attention. [10] Different alternative therapies viz. herbal as well as yoga are also incorporated in the treatment of epilepsy along with mainstream therapy of drugs and in some cases, surgery. These are a few of the factors that create the need and hence the pursuit for innovative compounds of plant origin with fewer redundant side effects. [11] Several reports are available regarding anticonvulsant activity of different plants and efforts for further exploration of their activity is still going on. [12] Indian traditional medicine system which offers many potential medicinal plants for epilepsy either in raw form or in the form of formulations. In Ayurveda, plants such as Embelia ribes, [13] Bacopa monnieri, Ziziyphus nummularia, Cajanus cajan, [14] Mimosa pudica, [15] etc., have been suggested to be used to control epilepsy. th century. [16] The present study was undertaken to evaluate the anticonvulsant activity of the polyherbal formulation using Maximal Electroshock Shock (MES) and Pentylenetetrazole (PTZ) induced convulsions in rats.
Materials and Methods

Materials
The plants materials A. racemosus (root), T. cordifolia (stem), C. pluricaulis (whole plant) and A. aspera (whole plant) were collected from the Rajiv Gandhi South Campus, Banaras Hindu University, Barkachha, Mirzapur, Uttar Pradesh in the month of March-April 2014. T. chebula (fruit), E. ribes (fruit), S. lappa (root) and A. calamus (root) were procured from a local market in Mirzapur. The botanical authentication of the specimens was done by Prof. Anil Kumar Singh, Institute of Medical Science, Banaras Hindu University; Varanasi, India. For further reference, the voucher specimens (APRL/HERB/13-14/102-109) of plant materials were deposited in Rajiv Gandhi South Campus, Banaras Hindu University, Barkachha, Mirzapur (U.P.) India.
Preparation of formulation
The shade dried plant materials were made into coarse powder separately with the help of a mechanical grinder and then mixed in a definite proportion. Extraction was performed with 98% methanol by cold maceration technique. After that, the extract was concentrated in a vacuum evaporator and the dried extract was obtained (17% w/w). The dry polyherbal extract was suspended in 5% carboxy methyl cellulose (CMC) solution before oral administration to animals.
Chemical
Pentylenetetrazole, phenytoin and diazepam were purchased from Sigma Chemical Co. (Delhi, India). NADH (Sisco Research Laboratories Pvt. Ltd, Mumbai), NBT (Sisco Research Laboratories Pvt. Ltd, Mumbai) and were used for the experiments. ELISA kit (MBS939900; MyBioSource, Inc., San Diego, CA, USA) was used for the estimation of GABA-T activity. All the reagents used were of analytical grade.
Pharmacological evaluation
Animals
Adult Charles Foster albino rats (150 ± 20 g) of either sex were procured from the Central Animal House, Institute of Medical Sciences, Banaras Hindu University (Registration No-542/AB/CPCSEA); Varanasi. The animals were kept in a temperature-controlled room (22 ± 2°C) with humidity (55 ± 10%) and 12 h light dark cycle. The animals were provided with standard pelleted feed (Amrit Pvt. Ltd. Pune, India) and fresh water ad libitum. Rats were kept at standard laboratory environment for at least one week before the experiment. The study has been approved by the Institutional Animal Ethical Committee (IAEC) (Dean/2014/CAEC/858).
In vivo anticonvulsant screening
Maximal electric shock induced seizures
The electroshock was applied via ear-clip electrodes of rats by using an electroconvulsometer (Techno., India). Saline and other individual drugs were given at appropriate times. The 150 mA current stimulus with 50 Hz frequency was given to the animals for 0.2 s. The animals were observed for the occurrence of hind limb tonic extension (HLTE) within 60 sec following the stimulus. The electrodes were dipped in normal saline before electroshock delivery. The rats were divided into 5 groups, consisting of 6 animals in each group (n = 6). Group 1 received only carboxymethyl cellulose (0.5% CMC, p.o.); Group 2 Received Phenytoin (25 mg/kg, i.p.) whereas, Group 3-5 Received PHF 100, 200, 400 mg/kg. b.w. p.o. respectively. After 30 min, electrical stimulation was given to all the animals in all 5 groups. The absence of hind limb tonic extensor was considered as full protection in the model. The beginning of stupor, percentage of protection against mortality as well as time taken for death/recovery was also recorded. [17] Pentylenetetrazole induced seizures
The PTZ-induced convulsion in animal model can be compared with myoclonic convulsions in human beings. The animals are divided into 6 subgroups each with 6 rats. Group I (normal control) received vehicle (0.5%
